Preclinical in vitro and in vivo studies demonstrated that TRB-PIM1, as well as IL7R positive T-ALL/LBL, benefit from treatments with one of the two pan-PIM inhibitors AZD1208 and TP3654, combined with glucocorticoids or chemotherapy. This evidence concerns the gene THRB and acute lymphoblastic leukemia.